The spring 2016 fellowship awardees have been announced! See who they are below.
If you would like to be the next fellowship awardee send us your application and tell us about your research project.
Short-term training is open to all registered EASL members, aiming to enhance the mobility of investigators within different European institutions through actively promoting scientific exchange among research units in Hepatology.
EASL offers a total yearly grant of €24,000 (12 x €2,000 per month). This amount is divided between the total number of successful awardees, according to the length of fellowships requested by the applicants. The maximum length of each fellowship must not exceed 3 months.
Applications ARE NOW OPEN
EASL offers two periods of short-term fellowship applications each year:
15 January -15 March & 15 July- 15 September
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that is characterized by steatosis and the presence of inflammation in the liver. Since the mechanisms by which inflammation is triggered are unknown, therapeutic options are poor and non-invasive markers to detect NASH do not exist. Our observations in hyperlipidemic mouse models clearly demonstrated that oxidative modification of lipids is an important trigger for hepatic inflammation. However, the precise mechanism by which oxidized lipids leads to hepatic inflammation is unknown.
The oxidation of lipids has been shown to result in the generation of various oxidation-specific epitopes that are recognized by specific antibodies. Current data from our lab clearly suggest that IgM antibodies targeting oxidized lipids are protective against the development of liver inflammation. Moreover, we have clear indications that plasma IgM levels can be used to diagnose NASH. Our planned studies will provide new insights regarding the molecular mechanisms driving hepatic inflammation, potentially deliver an innovative treatment for NASH and validate a non-invasive marker for the detection of hepatic inflammation.
|Sara Torrecilla Recio|
After obtaining my degree in Biomedical Science in 2013, I joined the research group of Liver Cancer Translational Research Laboratory in IDIBAPS-Hospital Clínic (Barcelona). As a PhD Student I have collaborated in different translational projects to uncover the molecular pathogenesis of Hepatocellular Carcinoma. I have been involved in pre-clinical studies aiming to evaluate anti-tumor efficacy of molecular targeted therapies as first-line or second-line in sorafenib-resistant tumours. My research has also focused on the application of high-throughput genomic data to study early molecular events of hepatocarcinogenesis. We are now interested in understanding the molecular pathogenesis of Nonalcoholic Steatohepatitis- related Hepatocellular Carcinoma, due to the significant increase in the incidence of this liver cancer subtype.
I have been interested in the impact of cirrhosis on the cardiac and circulatory function since my Medical school years when I published my first paper in the field. My research in this area became the focus of my Ph.D. studies and I initiated a prospective observational cohort study that is now moving into its’ final year of follow-up. Working on my thesis I became intrigued by the connections between cardiac and pulmonary vascular alterations at the level of pathophysiological processes as well as their clinical correlates. Asking the right questions about cirrhotic cardiomyopathy and hepato-pulmonary syndrome seems to me like a worthy goal, one that requires multicentric, international cooperation. Our plan is to use prospective and retrospective data from my home institution and the host centre in order to better characterize the diagnostic algorithm, describe epidemiological correlations and investigate the impact of hepato-pulmonary syndrome and cardiac dysfunction in cirrhotic patients. I am greatly excited by my short-term training that will take place in Hvidovre, as it is a reference center in Hepatology with an impressive caseload and experience in the field. It is my hope that we will be able to pool our data, offer new insights and further our knowledge of these frequent complications of liver disease.
Your application should include